Showing results (21-30 of 254) with videos related to
Sort By:
Pageof 26
Current Hematologic Malignancy Reports|October 23, 2018
Breast Implant-Associated Anaplastic Large Cell LymphomaP Rastogi, A K Deva, H Miles PrinceFrontiers in Immunology|March 22, 2021
Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory DrugsCriselle D'Souza, H Miles Prince, Paul J NeesonClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Clinical studies of histone deacetylase inhibitorsH Miles Prince, Mark J Bishton, Simon J HarrisonExpert Opinion on Investigational Drugs|April 28, 2007
Histone deacetylase inhibitors in cancer therapyWalid K Rasheed, Ricky W Johnstone, H Miles PrincePlastic and Reconstructive Surgery|March 30, 2012
Anaplastic large cell lymphoma and breast implants: five Australian casesKim O Taylor, Howard R Webster, H Miles PrinceThe Australasian Journal of Dermatology|November 30, 2012
Exacerbation of lymphomatoid papulosis during rituximab therapyOlivia McCurdy, Chris McCormack, David Ritchie, et al.Clinical Nuclear Medicine|October 5, 2019
A Novel Application of [18F]Fluorothymidine-PET ([18F]FLT-PET) in Clinical Practice to Quantify Regional Bone Marrow Function in a Patient With Treatment-Induced Cytopenias and to Guide "Marrow-Sparing" RadiotherapyBelinda A Campbell, Michael S Hofman, H Miles PrincePlatelets|June 2, 2015
Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case reportLouise Kostos, Kate Burbury, Gaurav Srivastava, et al.Future Oncology (London, England)|June 13, 2009
Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumorsH Miles Prince, Mark J Bishton, Ricky W JohnstoneThe Australasian Journal of Dermatology|February 14, 2004
Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two casesGlen A Kennedy, Robert Blum, Christopher McCormack, et al.Pageof 26